Pharmaceutical compounding group Fagron has completed two strategic acquisitions and announced the receipt of a new licence in North America.
The company acquired Amber Compounding Pharmacy, an established player in the compounding markets of Singapore and Malaysia. In addition, Fagron agreed to acquire Vepakum, a specialised packaging manufacturer. Completion of the Vepakum transaction remains subject to approval by Brazil’s competition authorities.
Fagron said the two businesses are expected to generate combined annual revenue of around €26 million, with an EBITDA margin above the group’s average. The total acquisition price amounts to approximately 55 million euros, implying a multiple of about eight.
Separately, Fagron obtained a licence from the California State Board of Pharmacy for its new Anazao Health facility in Tampa. The licence allows the company to ship patient-specific compounded medicines within the region.
